Dr Paul Finn, Chief Scientific Officer at Oxford Drug Design, explores the current use of AI in drug discovery and where the technology falls short. Nobody can have failed to notice the rapid entry of AI into many aspects of our daily lives; as a source of information and news, as notetakers, letter writers, image […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!